SANN.SW

Healthcare Biotechnology

Santhera Pharmaceuticals Holding AG

CHF 15.48

+0.24 +1.57% today

Price History

Not enough data

Key Stats

Market Cap

237.14M

Avg Volume

73,656

EPS

-CHF 2.24

52W High

CHF 18.84

52W Low

CHF 9.38

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

70.36

P/B Ratio

-17.55

P/S Ratio

2.34

EV/EBITDA

-60.94

EV/Revenue

2.18

Margins

Gross Margin 41.0%

Operating Margin (13.6%)

Net Margin (31.5%)

EBITDA Margin (3.6%)

Growth & Returns

Revenue Growth (YoY)

101.3%

Return on Assets

(3.9%)

Liquidity & Leverage

Current Ratio

1.73

Quick Ratio

1.10

Total Cash

41.77M

Total Debt

41.27M

About

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.